MIDD can ease pediatric & rare disease drug loss in Japan Blog MIDD 可缓解日本儿科及罕见疾病药物短缺问题 Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…Certara2025 年 7 月 8 日
Accelerating Oncology Drug FDA Submission with Project Management Services Case Study 通过项目管理服务加速肿瘤药物 FDA 申报流程 Discover how Certara’s dedicated project management and pharmacometric support helped an emerging biotech company fast-track…Certara2025 年 7 月 2 日
How Model-informed drug development rescue projects from a risky situation Case Study 如何通过模型引导的药物开发助力项目从高风险局面中脱困 Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…Certara2025 年 6 月 26 日
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara Webinar 从数据到决策:基于模型的荟萃分析(MBMA)与 GSK 和 Certara 真实世界影响 Certara2025 年 6 月 18 日
Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis On-Demand Webinar 革新传统 NCA 流程:ADNCA 技术助力合规化药代动力学分析 Certara2025 年 6 月 11 日
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer Publication Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…Certara2025 年 6 月 8 日
Pharmacokinetic Modeling of Neutralizing ADA Effects in Translational Development On-Demand Webinar 中和性抗糖尿病药物(ADA)效应的药代动力学建模在转化医学中的应用 Certara2025 年 5 月 21 日
Unlocking the Power of Oligonucleotide Therapeutics: A Model-Informed Approach with Certara & Ionis On-Demand Webinar 释放寡核苷酸疗法的力量:与 Certara 和 Ionis 合作,采用基于模型的方法 Clinical Pharmacology Leader, Ionis Pharmaceuticals Pratap Singh, Ph.D., is currently an Executive Director and Franchise…Certara2025 年 4 月 3 日
视频 Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara Certara2025 年 3 月 27 日